1. Home
  2. ACRS vs IDR Comparison

ACRS vs IDR Comparison

Compare ACRS & IDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$5.35

Market Cap

608.9M

Sector

Health Care

ML Signal

HOLD

Logo Idaho Strategic Resources Inc.

IDR

Idaho Strategic Resources Inc.

HOLD

Current Price

$28.77

Market Cap

502.0M

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACRS
IDR
Founded
2012
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Precious Metals
Sector
Health Care
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
608.9M
502.0M
IPO Year
2015
2000

Fundamental Metrics

Financial Performance
Metric
ACRS
IDR
Price
$5.35
$28.77
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$10.20
N/A
AVG Volume (30 Days)
2.0M
256.1K
Earning Date
05-07-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
69.01
70.15
EPS
N/A
0.40
Revenue
$1,683,000.00
$42,406,253.00
Revenue This Year
N/A
$25.52
Revenue Next Year
$4.24
N/A
P/E Ratio
N/A
$76.75
Revenue Growth
N/A
64.59
52 Week Low
$1.46
$16.03
52 Week High
$5.85
$54.70

Technical Indicators

Market Signals
Indicator
ACRS
IDR
Relative Strength Index (RSI) 55.46 35.63
Support Level $4.13 $26.81
Resistance Level $5.85 $41.05
Average True Range (ATR) 0.31 1.73
MACD -0.01 -0.08
Stochastic Oscillator 50.00 0.71

Price Performance

Historical Comparison
ACRS
IDR

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

About IDR Idaho Strategic Resources Inc.

Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. The Company's primary business is exploring for, developing, and extracting gold, and to a lesser extent, silver, and base metal mineral resources in the greater Coeur d'Alene Mining District of North Idaho. The Company produces gold at the Golden Chest Mine located in the Murray Gold Belt area of the world-class Coeur d'Alene Mining District, north of the prolific Silver Valley.

Share on Social Networks: